@article {HAYASHI1687, author = {KANA HAYASHI and KOTARO TOKUI and MINEHIKO INOMATA and KENJI AZECHI and ISAMI MIZUSHIMA and NAOKI TAKATA and CHIHIRO TAKA and SEISUKE OKAZAWA and KENTA KAMBARA and SHINGO IMANISHI and TOSHIRO MIWA and RYUJI HAYASHI and SHOKO MATSUI and SATOSHI NOMURA and KAZUYUKI TOBE}, title = {Case Series of Pleomorphic Carcinoma of the Lung Treated With Immune Checkpoint Inhibitors}, volume = {35}, number = {3}, pages = {1687--1692}, year = {2021}, doi = {10.21873/invivo.12428}, publisher = {International Institute of Anticancer Research}, abstract = {Aim: We report, herein, three cases of pleomorphic carcinoma of the lung treated with immune checkpoint inhibitors. Case 1: A 73-year-old man was diagnosed as having pleomorphic carcinoma of the lung and treated with pembrolizumab alone. However, he showed no response and died 4 months after the initiation of the treatment. Case 2: A 66-year-old man was diagnosed as having pleomorphic carcinoma of the lung. He was started on a combination regimen of pembrolizumab plus carboplatin plus nab-paclitaxel, and a remarkable response was observed. Case 3: A 49-year-old man was diagnosed as having pleomorphic carcinoma of the lung. He was started on pembrolizumab monotherapy as second-line treatment. Eleven months after the treatment initiation, computed tomography revealed the decrease of tumor diameter. Conclusion: Immune checkpoint inhibitor therapy is expected to improve the prognosis of patients with pleomorphic carcinoma of the lung.}, issn = {0258-851X}, URL = {https://iv.iiarjournals.org/content/35/3/1687}, eprint = {https://iv.iiarjournals.org/content/35/3/1687.full.pdf}, journal = {In Vivo} }